US FDA’s Review Performance Held Steady Despite Stormy First Quarter

 
• By Bridget Silverman
  
The FDA's review operations stayed on track despite the challenging environment in Q1 2025. (Shutterstock)

More from US FDA Performance Tracker

More from Geography